Medication-Induced Gingival Hyperplasia: Managing Plaque Retention from Calcium Channel Blockers

For people taking certain medicines to manage blood pressure or cardiovascular conditions, an unexpected oral-health complication can sometimes arise: medication-induced gingival hyperplasia. This refers to an overgrowth of gum tissue that is associated with specific drug classes, most notably calcium channel blockers. While not everyone taking these medicines will be affected, those who are may notice changes that make plaque removal genuinely more difficult. This article explains the condition, its relationship with plaque accumulation and what appropriate management may involve — for informational purposes only, and not as a substitute for personalised clinical advice. For support with plaque removal and gum care, professional dental hygiene services may be worth exploring.

What Is Medication-Induced Gingival Hyperplasia?

Gingival hyperplasia — also referred to as gingival overgrowth or gum enlargement — describes an abnormal increase in the volume of gum tissue. In medication-induced cases, the enlargement is associated with specific drugs rather than infection, systemic disease or local trauma alone.

The condition typically begins at the interdental papillae (the triangular sections of gum between the teeth) and can, in more pronounced cases, extend to cover a significant portion of the tooth surface. The tissue may appear firm, pale pink and relatively painless in early stages, though this varies. It is important to distinguish medication-associated enlargement from inflammatory swelling caused solely by gum disease, as the underlying mechanisms — and therefore management priorities — differ, even though they frequently coexist.

How Can Calcium Channel Blockers Affect the Gums?

Calcium channel blockers are a class of medicines widely used to treat hypertension, angina and certain cardiac arrhythmias. Several agents in this class have been associated with gingival hyperplasia, with amlodipine among those most frequently discussed in the dental literature. Nifedipine, which was studied earlier, showed notably higher rates of overgrowth in some reports, though individual response varies considerably.

The precise biological mechanism is not fully understood, but current evidence suggests that certain calcium channel blockers may alter fibroblast activity within the gum tissue, leading to an accumulation of connective tissue components. This results in the characteristic thickening and enlargement of the gingiva. Importantly, not every person taking a calcium channel blocker will develop this response. Reported prevalence estimates vary, and individual susceptibility appears to be influenced by factors including the specific drug, the dose, the duration of treatment, genetics and — crucially — the level of existing plaque and inflammation.

This means that two people taking the same medicine at the same dose may have very different outcomes, and that the severity of enlargement observed is not necessarily proportional to the medicine's cardiovascular effect.

Why Does Enlarged Gum Tissue Retain Plaque?

One of the significant secondary consequences of gingival enlargement is its effect on plaque retention and oral hygiene. As gum tissue increases in volume, it can form deeper pseudopockets — spaces between the gum and the tooth surface — that standard brushing cannot adequately reach. Plaque, the soft bacterial biofilm that forms continuously on teeth, accumulates in these areas with relative ease.

The relationship between plaque and enlargement is bidirectional in many cases. Whilst the medicine may initiate or predispose the tissue to overgrowth, plaque-associated inflammation can amplify the gingival response, making the enlargement more pronounced. Where inflammation has become established, periodontal treatment for inflamed gums may be discussed as part of a wider care plan. This is why oral hygiene levels at the time the medicine is introduced are thought to influence the degree of tissue change observed. Conversely, improved plaque control has been associated with a reduction in the inflammatory component of the enlargement, even when the drug-related component persists.

Bleeding on brushing, tenderness and difficulty manoeuvring cleaning aids around bulky tissue are common patient-reported challenges. These factors can discourage regular cleaning, which further allows plaque to accumulate — a cycle that underlines the importance of consistent oral-hygiene support.

How Can Plaque Retention Be Managed?

Managing plaque retention in the context of gingival hyperplasia requires a consistent, adapted approach to daily oral hygiene alongside periodic professional support.

Daily oral hygiene: Gentle, thorough brushing with a soft-bristled toothbrush, using a small-headed manual or electric brush to access areas close to the gum margin, remains the foundation. Angling the brush at approximately 45 degrees towards the gum line can help dislodge plaque at the gingival margin. Brushing twice daily for two minutes is a widely recommended minimum.

Interdental cleaning: Standard brushing does not clean between the teeth or within pseudopockets. Interdental brushes, floss or water-based interdental devices may help, though the most appropriate tool will depend on the size of the spaces and degree of tissue enlargement. Understanding electric and manual toothbrush differences can also inform the choice of daily cleaning aid. Selecting the right size and technique is an area where professional guidance is particularly valuable.

Professional dental cleaning: Supragingival (above the gum line) and, where appropriate, subgingival (below the gum line) professional cleaning can remove calculus and disrupted plaque from areas that are inaccessible to home care. For those experiencing plaque retention related to enlarged gums, airflow polishing for plaque removal is one approach that can form part of an ongoing maintenance plan.

Individualised advice: The most effective approach to plaque control in the context of altered gum anatomy is one that is tailored to the individual's mouth, medication history and hygiene habits by a suitably qualified dental professional.

Should You Stop Taking Calcium Channel Blockers?

This is a question that must be addressed by the prescribing clinician — not decided independently by the patient. Calcium channel blockers are frequently prescribed for significant cardiovascular conditions, and stopping or modifying them without medical supervision carries potentially serious health risks.

If medication-induced gingival hyperplasia is suspected, the appropriate course of action is to raise this concern with both your dentist and your prescribing doctor. In some circumstances, the prescriber may consider whether an alternative antihypertensive or cardiovascular medicine — one with a lower association with gingival changes — might be clinically appropriate. However, this is a decision that must be made on the basis of the individual's overall medical profile and cardiovascular risk, not on oral-health grounds alone.

It is also important to understand that switching medicine does not guarantee that enlarged gum tissue will fully reverse. Resolution varies between individuals and may be incomplete without additional dental assessment and, in some cases, further treatment. Do not stop or alter a prescribed calcium channel blocker without consulting your doctor.

When Should You Seek Dental Assessment?

Gum changes that develop or worsen while taking a calcium channel blocker warrant assessment by an appropriately qualified dental professional. You should consider seeking advice if you notice:

Disclaimer

This article is for general educational purposes only and is not a diagnosis or personalised medical advice. Symptoms, risks, and test suitability vary by individual and should be assessed by a qualified clinician. Seek urgent care or call 999 for severe or rapidly worsening symptoms.

Written Date: 26 October 2026 | Next Review Date: 26 October 2027